Skip to main content

Advertisement

SpringerLink
Log in

The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity

  • Urology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

To assess whether conservative treatment of pediatric patients with neurogenic detrusor overactivity (NDO) results in lower bladder pressure and increased expected bladder volume (EBV), we investigated the clinical and urodynamic effects of long-term intravesical oxybutynin instillation compared with a standard treatment of oral anticholinergic medication in patients with clean intermittent catheterization (CIC).

Methods

A retrospective study was performed including 21 patients suffering from myelomeningocele and NDO. Initially, all patients were treated with oral anticholinergics and CIC. Ten of the 21 patients showed a sufficient response to the treatment and were included in group I (anticholinergics and CIC). The other 11 patients responded poorly to the initial treatment or developed side effects to oral medication. These patients were included in group II and treated with intravesical oxybutynin and CIC. The two groups were compared using clinical, sonographic and urodynamic examinations performed prior to starting treatment and repeated on an annual basis. Changes from baseline were analyzed with the Mann–Whitney U test.

Results

Ten patients in group I and 11 in group II were investigated. Two of the 11 patients in group II stopped the treatment. The mean starting age was 8.1 (±6.6) years in group I and 12.5 (±4.5) years in group II. The mean follow-up time was 7.1 (±5.5) years in group I and 3.6 (±1.8) years in group II. Bladder capacity increased from 173 (±99) to 371 (±115) ml in group I and from 245 (±133) to 370 (±156) ml in group II. Six of the 10 patients in group I and 6/9 patients in group II reached normal EBV. Three of the 10 subjects in group I and 6/9 in group II had bladder compliance values >10 ml/cm H2O. At final follow-up, the overall rate of urinary tract infections was equal. Social continence was achieved in 6/10 in group I and 7/9 in group II. Altogether, 19/21 patients responded to conservative management.

Conclusions

In children with NDO, conservative medical treatment combined with CIC is feasible and provides an improved pattern of bladder function, which could help avoid bladder surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bauer SB (2003) The management of myelodysplastic child: a paradigm shift. BJU Int 92:23–28

    Article  PubMed  Google Scholar 

  2. Dik P, Klijn AJ, van Gool JD, van Steenwijk CC, de Jong TP (2006) Early start to therapy preserves kidney function in spina bifida patients. Eur Urol 49:908–913

    Article  PubMed  Google Scholar 

  3. Reitz A, Schurch B (2004) Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 42:267–272

    Article  PubMed  Google Scholar 

  4. Aslan AR, Kogan BA (2002) Conservative management in neurogenic bladder dysfunction. Curr Opin Urol 12(6):473–477

    Article  PubMed  Google Scholar 

  5. Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, Yoshimura N (2006) Local effect of antimuscarinics. Urol Clin North Am 33(4):511–518

    Article  PubMed  Google Scholar 

  6. Verpoorten C, Buyse GM (2008) The neurogenic bladder: medical treatment. Pediatr Nephrol 23:717–725

    Article  PubMed  Google Scholar 

  7. Nevèus T, von Gontard A, Hoebecke P, Hjälmas K, Bauer S, Bower W, Jorgensen TM, Rittig S, Walle JV, Yeung CK, Djurhuus JC (2007) The standardization of terminology of lower urinary tract function in children and adolescents: report from standardization committee of the international children’s continence society (ICCS). Neurourol Urodyn 26:90–102

    Article  Google Scholar 

  8. Palmer LS, Richards I, Kaplan W (1997) Age related bladder capacity and bladder capacity growth in children with myelomeningocele. J Urol 158(3Pt2):1261–1264

    PubMed  CAS  Google Scholar 

  9. Bauer SB (2008) Neurogenic bladder: etiology and assessment. Pediatr Nephrol 23:541–551

    Article  PubMed  Google Scholar 

  10. Amend B, Hennenlotter J, Schäfer T, Horstmann M, Stenzl A, Sievert KD (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side effects. Eur Urol 53(5):1021–1028

    Article  PubMed  CAS  Google Scholar 

  11. Takayanagi R, Mizushima H, Ozeki T, Yokoyama H, Iga T, Yamada Y (2007) Analysis of pharmacological Effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. Biol Pharm Bull 30(7):1297–1300

    Article  PubMed  CAS  Google Scholar 

  12. May K, Giessmann T, Wegner D, Oertel R, Modess C, Oswald S, Braeter M, Siegmund W (2008) Oral absorption of propiverine solution and of the immediate and extended release dosage forms; influence of regioselective intestinal elimination. Eur J Clin Pharmacol 64(11):1085–1092

    Article  PubMed  CAS  Google Scholar 

  13. Madersbacher H, Mürtz G, Alloussi S, Domurath B, Henne T, Körner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G (2009) Propiverine versus oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational study. BJU Int 103(6):776–781

    Article  PubMed  CAS  Google Scholar 

  14. Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ (2007) Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study. Eur Urol 51(1):235–242

    Article  PubMed  Google Scholar 

  15. Massad CA, Kogan BA, Trigo-Rocha FE (1992) The pharmacokinetics of intravesical and oral oxybutinin chloride. J Urol 148:595–597

    PubMed  CAS  Google Scholar 

  16. Buyse G, Verpoorten C, Vereecken R, Casaer P (1995) Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Paed Surg Suppl 1:31–34

    Article  Google Scholar 

  17. Lehtoranta K, Tainio H, Lukkari-Lax E, Hakonen T, Tammela TL (2002) Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 36(1):18–24

    Article  PubMed  CAS  Google Scholar 

  18. Amark P, Eksborg S, Juneskans O, Bussman G, Palm C (1998) Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. Br J Urol 82(6):859–864

    Article  PubMed  CAS  Google Scholar 

  19. Donnellan CA et al (1997) Oxybutynin and cognitive dysfunction. BMJ 315(7119):1363–1364

    Article  PubMed  CAS  Google Scholar 

  20. Ferrara P, D`Aleo CM, Tarquinin E, Salvatore S, Dalvaggio E (2001) Side-effect of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 87(7):674–678

    Article  PubMed  CAS  Google Scholar 

  21. Haferkamp A, Staehler G, Gerner HJ, Dörsam J (2000) Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 38:250–254

    Article  PubMed  CAS  Google Scholar 

  22. Hayashi A, Saito M, Okada S, Hanada T, Watanabe T, Satoh K, Kanzaki S (2007) Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children. J Pediatr Urol 3:438–442

    Article  PubMed  Google Scholar 

  23. Amark P, Bussman G, Eksborg S (1998) Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 34(2):148–153

    Article  PubMed  CAS  Google Scholar 

  24. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515

    Article  PubMed  CAS  Google Scholar 

  25. Do Ngoc Thanh C, Audry G, Forin V (2009) Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. J Pediatr Urol 5(6):430–436

    Article  PubMed  CAS  Google Scholar 

  26. Gamé X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G, Denys P, De Seze M, Haab F, Karsenty G, Kerdraon J, Perrouin-Verbe B, Ruffion A, Soler JM, Saussine C (2009) Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 5(3):156–164

    Article  PubMed  Google Scholar 

  27. Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66(4):865–870 discussion 870

    Article  PubMed  Google Scholar 

  28. Ab E, Dik P, Klijn AJ, van Gool JD, de Jong TP (2004) Detrusor overactivity in spina bifida: how long does it need to be treated? Neurourol Urodyn 23(7):685–688

    Article  PubMed  Google Scholar 

  29. Riccabona M, Koen M, Schindler M, Beckers G, Pycha A, Lusuardi L, Bauer SB (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171(2 Pt 1):845–848

    Article  PubMed  CAS  Google Scholar 

  30. Romero RM, Rivas S, Parente A, Fanjul M, Angulo JM (2011) Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity. Actas Urol Esp 35(2):89–92

    Article  PubMed  CAS  Google Scholar 

  31. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ (2009) European consensus panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119

    Article  PubMed  CAS  Google Scholar 

  32. Moore C, Kogan BA, Parekl A (2004) Impact of urinary incontinence on self-concept in children with spina bifida. J Urol 171(4):1659–1662

    Article  PubMed  Google Scholar 

  33. Borzyskowski M, Cox A, Edwards M, Owen A (2004) Neuropathic bladder and intermittent catheterization: social and psychological impact on families. Dev Med Child Neurol 46(3):160–167

    Article  PubMed  Google Scholar 

  34. George J, Tharion G, Richar J, Macaden AS, Thomas R, Bhattacharji S (2007) The effectiveness of intravesical oxybutynin, propantheline and capsaicin in the management of neuropathic bladder following spinal cord injury. Sci World J 7:1683–1690

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The work described has been presented in part at the 51st Annual Meeting of the “Society for Research into Hydrocephalus and Spina Bifida” and has been published as an abstract in “Cerebrospinal Fluid Research”.

Conflict of interest

The authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pediatric Surgery, University of Leipzig, Leipzig, Germany

    Thomas Lehnert, Margit Weisser & Holger Till

  2. Department of Pediatric Surgery, Goethe-University Frankfurt/M, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    Udo Rolle

Authors
  1. Thomas Lehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margit Weisser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Holger Till
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Udo Rolle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Udo Rolle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehnert, T., Weisser, M., Till, H. et al. The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity. Int Urol Nephrol 44, 335–341 (2012). https://doi.org/10.1007/s11255-011-0030-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-011-0030-y

Keywords

Search

Navigation